Boehringer Ingelheim Announces Management Changes
With the recent acquisition of Ben Venue Laboratories Inc., Boehringer Ingelheim Corp. has made a number of strategic changes to its Ethical Pharmaceuticals business unit. The companies involved in the Business Unit reorganization include Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, CT), Roxane Laboratories Inc. (Columbus, OH), and Ben Venue Laboratories Inc., (Bedford, OH) itself. The organization will continue to maintain separate legal entities for the three subsidiaries.
The following key staffing changes have been announced:
- Dr. Kirk Shepard, previously sr. vice president, Medical, Marketing and Sales at Roxane Laboratories will take on the role as sr. vice president, Business Unit Rx/Hospital Strategy.
- Tom Russillo, president and COO of Ben Venue Laboratories Inc. will add to his current responsibilities the multi-source business at Roxane Laboratories. The Roxane Laboratories Scientific Affairs and Drug Regulatory Affairs Departments for New Products will also report to Russillo.
- Greg Fulton has been promoted to head of Branded Marketing, Boehringer Ingelheim Pharmaceuticals Inc./Roxane Laboratories.
- James King has been promoted to head of Branded Sales, Boehringer Ingelheim Pharmaceuticals Inc./Roxane Laboratories Inc. King also will be responsible for Sales Training and Development, Sales Fleet and Business Technology for the Business Unit.
- Mike Leonetti, previously director of Organizational Effectiveness, will lead the Business Unit's Managed Care and Trade Relations organizations as head of Managed Care and Trade Relations.
Boehringer Ingelheim Pharmaceuticals and Roxane Laboratories Contracting will be combined into a single organization in the Business Unit reporting to Gregg Ciarelli, in his new role as head of Contracting, Pricing & Market Controlling. Dr. Ulrich Drees continues as head of Project Management.
For more information: Boehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Rd., Ridgefield, CT 06877-0368, USA.